Dengue Testing - Market Share Analysis, Industry Trends & Statistics, Growth Forecasts (2026-2031)

Dengue testing market size in 2026 is estimated at USD 474.01 million, growing from 2025 value of USD 455.25 million with 2031 projections showing USD 579.72 million, growing at 4.12% CAGR over 2026-2031. This report is Segmented by Diagnostic Technology (NS1 Antigen Tests, IgM/IgG Serology ELISA, RT-PCR Molecular Tests, Combination/Panel Assays, Novel Biosensor-Based Tests), End-User (Hospitals & Clinics, Diagnostic Laboratories, and More), Sample Type (Serum/Plasma, Whole Blood, and More), and Geography (North America, Europe, and More). The Market Forecasts are Provided in Terms of Value (USD).

Global Dengue Testing Market Trends and Insights

Rising Dengue Incidence & Frequent Outbreaks

Global case counts surpassed 6.5 million in 2024, tripling historical averages and triggering widespread laboratory confirmation requirements. Securing accurate differentiation from malaria, typhoid, and other febrile illnesses became a clinical priority, pushing demand for dependable diagnostic kits. Economic losses tied to misdiagnosis encouraged hospitals to adopt rapid assays that deliver results within 48 hours. Outbreak seasonality varied by hemisphere, ensuring steady year-round test volumes. Health agencies responded with bulk-procurement frameworks that locked-in minimum purchase quantities and guaranteed supplier revenues.

WHO-Led Push for Early Laboratory Confirmation and Surveillance

Updated 2024 WHO guidance requires lab confirmation for suspected cases, converting sporadic testing into standardized fever-screening programs. Endemic nations adopted WHO-prequalified kits to meet reporting obligations under the Global Health Observatory. Integration with digital surveillance platforms accelerated transmission mapping and stock planning. This shift favored manufacturers able to provide validated performance data and electronic data-capture interfaces. Long-term demand is bolstered by donor-funded initiatives that underwrite kit costs in resource-constrained settings.

Variable Sensitivity/Specificity of Many Rapid Kits

Clinical evaluations show sensitivity ranging from 45% to 90% across brands, creating uncertainty among frontline clinicians. Substandard kits erode confidence and push procurement toward laboratory-based assays, lengthening turnaround times. LMIC regulators often lack resources for rigorous pre-market reviews, allowing inferior products into distribution. This dynamic prolongs sales cycles for high-quality suppliers that must present comparative data. Market educators now emphasize head-to-head performance studies to restore trust.

Other drivers and restraints analyzed in the detailed report include:

• Adoption Surge of Rapid NS1 Antigen Point-of-Care Tests
• Pre-Vaccination Serostatus Screening Mandates (CYD-TDV & TAK-003)
• Cross-Reactivity with Other Flaviviruses Muddying Results

Segment Analysis

NS1 antigen assays generated 42.68% of the dengue testing market share in 2025 by providing early detection during the viraemic window when interventions yield the greatest clinical value. Yet the dengue testing market is witnessing the fastest acceleration in combination/panel assays at a 4.89% CAGR through 2031 as clinicians demand simultaneous differentiation among co-endemic viruses. The dengue testing market size for multiplex panels is projected to widen as public-health agencies standardize outbreak response algorithms on multi-pathogen detection. RT-PCR continues as the reference confirmation tool, especially for research and serotype surveillance. Biosensor-based platforms, employing electrochemical or optical readouts, promise laboratory-grade sensitivity in portable formats, creating an inflection point once regulatory approval is secured.

Emerging technology suppliers integrate artificial-intelligence modules to interpret weak signal bands, reducing reader subjectivity and improving field accuracy. Regulatory scrutiny remains intense, with FDA 510(k) clearances contingent upon robust cross-reactivity data. Successful approvals can reorder competitive hierarchies as buyers consolidate around high-performance multiplex systems.

Complete Report Scope:

• By Diagnostic Technology (Value)
  • NS1 Antigen Tests
  • IgM/IgG Serology ELISA
  • RT-PCR Molecular Tests
  • Combination/Panel Assays
  • Novel Biosensor-based Tests
• By End-User (Value)
  • Hospitals & Clinics
  • Diagnostic Laboratories
  • Home Care / Self-Testing
  • Others
• By Sample Type (Value)
  • Serum / Plasma
  • Whole Blood (Finger-stick / Venous)
  • Saliva / Oral Fluid
  • Others (Urine, Dried-Blood-Spot)
• By Geography (Value)
  • North America
    • United States
    • Canada
    • Mexico
  • South America
    • Brazil
    • Argentina
    • Rest of South America
  • Europe
    • United Kingdom
    • Germany
    • France
    • Spain
    • Italy
    • Russia
    • Rest of Europe
  • APAC
    • China
    • India
    • Japan
    • South Korea
    • Australia
    • Rest of APAC
  • Middle East and Africa
    • GCC
    • South Africa
    • Rest of Middle East and Africa

Geography Analysis

North America delivered 24.05% of global revenue in 2025, supported by robust insurance coverage and travel-screening programs that extend beyond endemic zones. U.S. states such as Florida implemented routine Aedes surveillance, driving continual procurement of multiplex kits. Canada’s demand centers on major airports and urban hospitals, while Mexico’s endemic burden secures government tenders for both rapid and laboratory assays. The dengue testing market size in North America benefits from early adoption of digital reporting mandates, incentivizing integrated analyzer connectivity.

Asia-Pacific records the highest regional growth at a 4.79% CAGR through 2031, propelled by India’s national vector-borne disease strategies and China’s urban health reforms. Thailand and Vietnam sustain elevated per-capita test rates due to hyperendemic transmission, whereas Singapore deploys airport-based rapid screening for incoming travelers. South Korea prioritizes imported case detection, leveraging centralized labs to manage seasonal spikes. Australia’s northern territories maintain steady demand, with preparedness budgets funding diagnostic stockpiles against potential southward vector spread.

South America advances on the back of Brazil’s dominant spend and Argentina’s expanding lab capacity. Brazil’s experience handling concurrent dengue, Zika, and Chikungunya epidemics underpins aggressive multiplex adoption. Europe registers moderated growth, concentrated around Mediterranean countries where Aedes albopictus establishes seasonal footholds. The Middle East and Africa present a heterogeneous picture: Gulf Cooperation Council members focus on travel-related testing, while sub-Saharan nations grapple with supply constraints that hamper widespread deployment despite high disease incidence.

List of Companies Covered in this Report:

• Abbott Laboratories

Additional Benefits:

• The market estimate (ME) sheet in Excel format
• 3 months of analyst support